Cellular Origins

Explore the latest insights on Cellular Origins and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Cellular Origins’ developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Company Drug

Sichuan Biokin’s Izalontamab Brengitecan (BL‑B01D1) Gains NMPA Acceptance for HR+/HER2‑ Breast Cancer NDA – Phase III PFS Win Drives Third Tumor‑Type Expansion Bid

Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that China's National Medical Products Administration (NMPA) has officially accepted the marketing application for a new indication of Izalontamab Brengitecan (BL‑B01D1 /…

October 23, 2026

Gilead to Acquire Oral IL‑23R Inhibitor HCXT‑2001 from PepStar Therapeutics for USD 1.275 Billion Upfront – Deepening Inflammation Pipeline with Long‑Acting Macrocyclic Peptide

October 23, 2026

Everest Medicines Secures TFDA Approval for Velsipity (etrasimod) in Ulcerative Colitis – Completion of All Authorized Territories Across Greater China and South Korea

October 23, 2026

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.

Explore Now

Company Deals